ReviewTrends in parasitology2022
The assessment of antimalarial drug efficacy in vivo.
Review in Trends in parasitology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.Lancet (London, England) · 2023Trial
- Parasitological efficacy of seasonal malaria chemoprevention in Nampula, northern Mozambique.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Article
- The Importance of Murine Models in Determining In Vivo Pharmacokinetics, Safety, and Efficacy in Antimalarial Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Emerging trends and new developments in global research on artemisinin and its derivatives.Heliyon · 2025Article
- Application of a new highly multiplexed amplicon sequencing tool to evaluatemedRxiv : the preprint server for health sciences · 2024Article
- Antimalarial activity of borrelidin and fumagilin inOpen veterinary journal · 2024Article
- Application of a new highly multiplexed amplicon sequencing tool to evaluateFrontiers in parasitology · 2024Article
- A proposed method of grading malaria chemoprevention efficacy.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2023Article
- Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria.PLoS medicine · 2023Article
- Seasonal malaria chemoprevention in Africa and China's upgraded role as a contributor: a scoping review.Infectious diseases of poverty · 2023Article
- Climate variability, socio-economic conditions and vulnerability to malaria infections in Mozambique 2016-2018: a spatial temporal analysis.Frontiers in public health · 2023Article
- Targeting malaria parasites inside mosquitoes: ecoevolutionary consequences.Trends in parasitology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Currently recommended methods of assessing the efficacy of uncomplicated falciparum malaria treatment work less well in high-transmission than in low-transmission settings. There is also uncertainty how to assess intermittent preventive therapies and seasonal malaria chemoprevention (SMC), and Plasmodium vivax radical cure. A pharmacometric antimalarial resistance monitoring (PARM) approach is proposed specifically for evaluating slowly eliminated antimalarial drugs in areas of high transmission. In PARM antimalarial drug concentrations at recurrent parasitaemia are measured to identify outliers (i.e., recurrent parasitaemias in the presence of normally suppressive drug concentrations) and to evaluate changes over time. PARM requires characterization of pharmacometric profiles but should be simpler and more sensitive than current molecular genotyping-based methodologies. PARM does not require parasite genotyping and can be applied to the assessment of both prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.